<DOC>
	<DOCNO>NCT01697345</DOCNO>
	<brief_summary>It well document woman breast cancer may experience decrease quality life sexual functioning due side effect adjuvant endocrine therapy , typically aromatase inhibitor ( AIs ) . Women take AIs likely report unpleasant urogenital vaginal symptom due physiologic suppression estradiol . This treatment impair sexual functioning cause decrease sexual health quality life . At present time , Food Drug Administration ( FDA ) approve medication vulvovaginal sexual side effect relate use AIs . The lack treatment option concern number woman diagnose breast cancer continue increase ; longevity , also , continue increase use newer adjuvant chemotherapy . Local health care practitioner observe benefit vaginal testosterone sexual health breast cancer survivor similar benefit vaginal estrogen woman without breast cancer . The purpose study evaluate impact use daily compound vaginal testosterone cream 4 week ( 28 day ) breast cancer survivor 's reported experience vulvovaginal symptom accompany use AIs associate quality life sexual functioning .</brief_summary>
	<brief_title>Breast Cancer , Aromatase Inhibitor Therapy , Sexual Functioning : The Effects Vaginal Testosterone Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Women breast cancer Currently take aromatase inhibitor ( AI ) Age &gt; 50 year age Postmenopausal , two year since last menstrual cycle Urogenital/vulvovaginal symptom vaginal dryness pain intercourse Changes sexual health quality life/sexual functioning since start AI therapy The use treatment breast cancer chemotherapy radiation within past 12 month A known sensitivity medication contain testosterone The use exogenous hormone replacement therapy ( HRT ) past three month , include systemic local estrogen testosterone therapy</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Vaginal Testosterone</keyword>
	<keyword>Vaginal atrophy</keyword>
	<keyword>Female Sexual Dysfunction</keyword>
	<keyword>Aromatase Inhibitors</keyword>
</DOC>